Addex Therapeutics (ADXN) Projected to Post Quarterly Earnings on Monday

Addex Therapeutics (NASDAQ:ADXN) is expected to issue its quarterly earnings data before the market opens on Monday, March 24th. Analysts expect the company to announce earnings of ($1.42) per share and revenue of $0.15 million for the quarter.

Addex Therapeutics Price Performance

Shares of ADXN stock opened at $7.92 on Friday. The company’s fifty day simple moving average is $7.71 and its two-hundred day simple moving average is $8.68. Addex Therapeutics has a 1 year low of $6.67 and a 1 year high of $27.90. The stock has a market capitalization of $8.39 million, a price-to-earnings ratio of -23.28 and a beta of 1.76.

About Addex Therapeutics

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.